Modeling the Competition between Misfolded Aβ Conformers That Produce Distinct Types of Amyloid Pathology in

Guilian Xu1,2,3, Susan Fromholt1,2,3, David R Borchelt1,2,3

  • 1Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 32610, USA.

Biomolecules
|July 27, 2022
PubMed

Insights

Alzheimer's disease (AD) amyloid pathology may stem from distinct misfolded amyloid-beta (Aβ) conformers, akin to prions. These Aβ strains can compete and propagate within the brain, influencing AD progression.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pathology

Background:

  • Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) pathology, presenting as fibrillary or diffuse deposits.
  • These Aβ pathologies exhibit differential binding affinities to amyloid dyes like Thioflavin-S and Congo Red.
  • Evidence suggests that distinct Aβ conformers or strains may propagate pathology, similar to prions.

Purpose of the Study:

  • To investigate the propagation and competition dynamics of different Aβ strains in vivo.
  • To determine if distinct Aβ conformers can outcompete resident pathologies in transgenic mouse models of AD-amyloidosis.

Main Methods:

  • Injected distinct Aβ strains (cored-neuritic and diffuse) from AD models into newborn transgenic mice.
  • Utilized three different transgenic host models with varying resident Aβ pathologies (diffuse or cored-neuritic).
  • Performed serial passaging experiments to assess strain propagation efficiency.

Main Results:

  • Injected Aβ strains successfully propagated and, depending on host transgene expression, outcompeted resident pathologies.
  • The diffuse Aβ strain demonstrated more efficient propagation compared to the cored-neuritic strain.
  • Strain competition dynamics were observed, suggesting a hierarchy in Aβ conformer propagation.

Conclusions:

  • Different Aβ pathologies in AD brains likely arise from distinct Aβ conformer populations.
  • These Aβ conformers compete to establish pathology, influencing disease progression.
  • Understanding Aβ strain diversity is crucial for developing targeted AD therapies.